Name: Eye on the Cure Podcast | Episode 64: Dr. Kapil Bharti by Foundation Fighting Blindness
Duration: 27 min 10 s
Description: Kapil Bharti, PhD, a senior investigator and director of the Intramural Research Program at the National Eye Institute (NEI), talks with host Ben Shaberman about his clinical trial underway for an innovative cell therapy for geographic atrophy (advanced dry age-related macular degeneration) as well as a clinical trial of the drug metformin for Stargardt disease.

The gene therapy is administered using a less-invasive intravitreal injection.

ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations

The drug is thought to work independent of the mutated gene causing RP.

Phase 3 Clinical Trial of NAC Launched for RP Patients

Kapil Bharti, PhD, a senior investigator and director of the Intramural Research Program at the National Eye Institute (NEI), talks with host Ben Shaberman about his clinical trial underway for an innovative cell therapy for geographic atrophy (advanced dry age-related macular degeneration) as well as a clinical trial of the drug metformin for Stargardt disease.

Eye on the Cure Podcast | Episode 64: Dr. Kapil Bharti

The company’s innovative Gene Coding™ platform enables seamless insertion of DNA into selective genomic locations.

SalioGen Developing Novel Gene Insertion Therapy for Stargardt Disease

Matthew Whitaker talks to host Ben Shaberman about his remarkable achievements and success as a young jazz pianist and composer. Matthew was born three months prematurely and weighed less than two pounds. The oxygen he needed to stay alive also caused total blindness. But now 23 years old, the renowned music prodigy has recorded four albums, received several honors and awards, and appeared on TV shows such as Showtime at the Apollo, the Today Show, Ellen, and 60 Minutes.

Eye on the Cure Podcast | Episode 65: Matthew Whitaker

The XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.

Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial

The Foundation Fighting Blindness is committed to finding treatments and cures for blinding retinal diseases that affect more than 10 million people in the United States. To learn more, go to FightingBlindness.org.

Eye on the Cure Podcast | Episode 64: Dr. Kapil Bharti

Foundation Fighting Blindness

Related tracks